Drug Search Results
More Filters [+]

Glycopyrronium

Alternative Names: glycopyrronium, seebri, drm-04, drm04, drm 04, qbrexza, qva-149, qva149, qva 149, wo-3970, wo3970, wo 3970, glycopyrroniumbromid
Latest Update: 2024-02-14
Latest Update Note: Clinical Trial Update

Product Description

Glycopyrronium (Qbrexza) topical wipes are labeled for the treatment of hyperhidrosis. Glycopyrronium wipes contain a topically-dosed anticholinergic. When applied to the axillae, they reduce sweating in patients nine years and older with hyperhidrosis (Sourced from: https://www.aafp.org/afp/2019/0915/p372.html)

Mechanisms of Action: M1 Antagonist,M2 Antagonist,M3 Antagonist,M4 Antagonist,M5 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Chronic Obstructive Pulmonary Disease | Hyperhidrosis

Known Adverse Events: Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Headache | Pain Unspecified | Erythema | Pruritus | Keratoconjunctivitis Sicca | Mydriasis | Constipation

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Glycopyrronium

Countries in Clinic: Argentina, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Finland, Germany, Guatemala, Hungary, India, Israel, Japan, Korea, Malaysia, Mexico, Netherlands, Philippines, Poland, South Africa, Spain, Thailand, Turkey, United Kingdom, United States, Vietnam

Active Clinical Trial Count: 22

Highest Development Phases

Phase 3: Asthma|Asthma, Allergic|Chronic Obstructive Pulmonary Disease|Hyperhidrosis

Phase 2: COVID-19

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TRIPLAR

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

2027-11-30

74%

TRIPLAR

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

2027-11-30

74%

TRIPLAR

P3

Not yet recruiting

Chronic Obstructive Pulmonary Disease

2027-11-30

74%

D5985C00002

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-09-05

74%

D5985C00002

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-09-05

74%

D5985C00002

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-09-05

74%

ATHLOS

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-08-24

74%

ATHLOS

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-08-24

74%

ATHLOS

P3

Recruiting

Chronic Obstructive Pulmonary Disease

2025-08-24

74%

CQVM149C2201

P2

Recruiting

Asthma

2025-05-09

35%

Recent News Events